News
-
-
-
COMMUNIQUÉ DE PRESSE
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
SCHOTT Pharma AG & Co. KGaA delivers on 2023 targets with 9% revenue growth to EUR 899m and maintains high EBITDA margin of 26.6%. Strategic shift towards high-value solutions accelerates with strong profitability. -
-
COMMUNIQUÉ DE PRESSE
SCHOTT Pharma IPO: Final offer price set at EUR 27.00 per share
-
-
-
COMMUNIQUÉ DE PRESSE
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma plans Initial Public Offering
-
-